In adults with treatment-resistant depression, does psilocybin-assisted therapy lead improved mental health outcomes rates compared to pharmacotherapy

August 19, 2023August 19, 2023 Discipline: Research Methods

So bascially i am writing a literture review on the above question “In adults with treatment-resistant depression, does psilocybin-assisted therapy lead improved mental health outcomes rates compared to pharmacotherapy”. I have found my 10-12 articles required for the review. However we are required provide a  “summary table” using the matrix method, instructions on what to put in matrix table is as follows  


SUMMARY TABLE: 
– Authors/Year of publication
–  Country of origin
– Aim/Purpose of Study (for eg to examine the effects of psilocybin on mental health” 
– Methodology ( for eg qualitive, quantative or mixed method) 
–  Participants/sample size (for eg 20 patients 4 female and 16 male) 
–  Data collection procedure (this is one i am aparticulary struggilling with) 
–  Data Analysis (this is one i am aparticulary struggilling with) 
–  Limitations (for eg small sample size) 
– Key findings 
–  Quality appraisal scores (CASP tool) in percentage form (attachement of CASP tool qquestions, basically need to use it to on each article to see how many questions out of 10 are yes giving you a percentage) 

 There is no word limit on the matrix method however the provided sample will give you input of how much information to inclue, really just dot points. 

Next, the discussion part of the review,  600 words required and the instructions are as follows.

DISCCUSION:  
–       3-4 paragraphs discussing the findings of the articles and any themes identified between them. Subheadings may be used to organise this section. 

–        The discussion should include recommendations for clinical practice and/or future research. 

–        A limitations section should be provided at the end of the discussion section. Limitations may refer to either the literature review process e.g. “The search strategy only considered articles published in the English language” or limitations identified from the selected articles e.g. “The findings from these studies are applicable to an acute care setting only and therefore may not be generalisable to alternative settings.”


ARTICLES TO BE USED: 

1.    Article 3: Rootman, J. M., Kryskow, P., Harvey, K., Stamets, P., Santos-Brault, E., Kuypers, K. P. C., Polito, V., Bourzat, F., & Walsh, Z. (2021). Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific Reports, 11(1), 22479–22479. https://doi.org/10.1038/s41598-021-01811-4

 

2.    Article 4: Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., & Shannon, K. (2017). Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open, 7(9), e016025–e016025. https://doi.org/10.1136/bmjopen-2017-016025

 

3.    Aritcle 5: Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology (Oxford), 36(2), 151–158. https://doi.org/10.1177/02698811211073759

 

4.    Article 6: Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology (Oxford), 34(2), 155–166. https://doi.org/10.1177/0269881119897615

 

 

5.    Article 8: Niles, H., Fogg, C., Kelmendi, B., & Lazenby, M. (2021). Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliative Care, 20(1), 191–191. https://doi.org/10.1186/s12904-021-00889-x

 

 

6.    Article 10: Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., Leech, R., Curran, H. V., & Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7(1), 13187–11. https://doi.org/10.1038/s41598-017-13282-7

 

7.    Article 11: Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 235(2), 399–408. https://doi.org/10.1007/s00213-017-4771-x

 

8.    Article 12: Rucker, J., Jafari, H., Mantingh, T., Bird, C., Modlin, N. L., Knight, G., Reinholdt, F., Day, C., Carter, B., & Young, A. (2021). Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. BMJ Open, 11(12), e056091–e056091. https://doi.org/10.1136/bmjopen-2021-056091

 

9.    Article 13: Jones, G. M., & Nock, M. K. (2022). Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. Scientific Reports, 12(1), 16976–16978. https://doi.org/10.1038/s41598-022-18645-3

 

 

10. Article 15: Soares, C. M., Leite, Ângela, & Pinto, M. (2023). Self-Care Practices with Psychedelics – A Qualitative Study of Users’ Perspectives. Journal of Psychoactive Drugs, 55(2), 159–169. https://doi.org/10.1080/02791072.2022.2071134

 

11. Article 17: Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022). Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. Journal of Psychopharmacology (Oxford), 36(1), 31–45. https://doi.org/10.1177/02698811211066709

 

 

12. Artile 19: Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023). Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal of Psychopharmacology (Oxford), 37(7), 698–706. https://doi.org/10.1177/02698811231154852


ONLY 10-12 articles are needed so if you find 1 or 2 that is not adeuqate for the literature review feel free to remove and let me know the reasons why. The rest of the review i am fine with its just these 2 parts 

Are you struggling with your paper? Let us handle it - WE ARE EXPERTS!

Whatever paper you need - we will help you write it

Get started

Starts at $9 /page

Login Register Reset

How our paper writing service works

It's very simple!

  • Fill out the order form

    Complete the order form by providing as much information as possible, and then click the submit button.

  • Choose writer

    Select your preferred writer for the project, or let us assign the best writer for you.

  • Add funds

    Allocate funds to your wallet. You can release these funds to the writer incrementally, after each section is completed and meets your expected quality.

  • Ready

    Download the finished work. Review the paper and request free edits if needed. Optionally, rate the writer and leave a review.

Place order now